| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5498040 | International Journal of Radiation Oncology*Biology*Physics | 2017 | 21 Pages |
Abstract
Capecitabine can be safely administered on radiation days with careful clinical monitoring and was associated with encouraging response in this chemo-refractory cohort. However, patients with TN breast cancer had poor outcomes even when response was achieved. Further study in non-TN patients may be warranted.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Wendy A. MD, PhD, Penny MD, Lisa RN, Hui PhD, Evan N. PhD, James M. PhD, Vicente MD, Huong MD, Lavinia P. MD, Gildy V. MD, Eric A. MD, Welela MD, MPH, Karen MD, MHSc, MPH, Benjamin D. MD, Thomas A. MD, George H. MD, PhD,